Kornimate/medical-research-clean huggingface dataset:
effect of priming during induction and consolidations in younger acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is: 1. to compare priming with granulocyte-macrophage colony-stimulating factor (gm-csf) during induction and consolidation courses versus no priming. 2. to compare as consolidation timed sequential chemotherapy versus four courses of high dose cytarabine.

patients aged 15-50 are enrolled and randomly assigned to receive gm-csf or no gm-csf during all remission-induction and consolidation courses of chemotherapy. induction chemotherapy consists of a timed-sequential chemotherapy including a first sequence of chemotherapy combining daunorubicin, 80 mg/m2 per day, administered iv as a short infusion over 3 days (days 1-3), and cytarabine, 500 mg/m2 per day iv as a continuous infusion over the same period. the second sequence, administered after 4-day free interval, consists of mitoxantrone, 12 mg/m2 per day, administered iv as a short infusion over 2 days (days 8 and 9), and cytarabine, 500 mg/m2/12h, administered as a 3-hour infusion for 3 days (days 8-10). salvage therapy consists of cytarabine, 3 g/m2/12h on days 1,3,5,7, combined with amsacrine, 100mg/m2 per day on days 1 to 3. gm-csf (leucomax, recombinant human gm-csf from escherichia coli, schering plough, kenilworth,n.j., usa) is given at a dose of 5µg/kg per day, intravenously beginning at day 1 of each chemotherapy course and continuing until the last day of chemotherapy of each course. patients who achieve cr after induction chemotherapy or salvage therapy are randomly assigned to consolidation courses consisting of either a timed sequential chemotherapy similar to that of the alfa-9000 trial (p2 arm) or the calgb postremission chemotherapy (p1 arm), which includes 4 cycles of high-dose cytarabine, followed by 4 additional maintenance courses.

Eligibility criteria:
inclusion criteria: * a morphologically proven diagnosis of aml according to the who classification * serum creatinine \< 2n; ast and alt \< 2.5n; total bilirubin \< 2n (unless related to the underlying disease). * ecog performance status 0 to 2. * women of child-bearing must use acceptable contraceptive methods, and must have a negative serum or urine pregnancy test within 2 weeks prior the beginning treatment on this trial. * must be able and willing to give written informed consent exclusion criteria: * patients with m3-aml. patient with aml following diagnosed myeloproliferation or patient with prior history of mds known for more than 3 months. patients with aml secondary to previous treatment with cytotoxic chemotherapy or radiotherapy (therapy-related aml). * patient presenting any diagnosis of uncontrolled or metastatic tumor. * patients with uncontrolled severe infection,

Keywords: acute myeloid leukemia priming gm-csf timed-sequential chemotherapy prognosis
effects of kinesio taping in addition to routine physical therapy on pain, range of motion and functional disability in patients with upper cross syndrome

Conditions: Cervical Pain

Summary: objective of the study is to compare the effects of kinesio taping and routine physical therapy on pain, range of motion and functional disability in patients with upper cross syndrome.it is a single blinded randomized controlled trial using non probability purposive sampling technique. alternative hypothesis: there is a significant difference in the effects of routine physical therapy with and without kinesio taping on pain, range of motion and functional disability in patients with upper cross syndrome. null hypothesis: there is no significant difference in the effects of routine physical therapy with and without kinesio taping on pain, range of motion and functional disability in patients with upper cross syndrome.

it will be a prospectively registered ,parallel designed, randomized controlled trial with concealed allocation. subjects will be selected from the outpatient department of physical therapy, the university of lahore teaching hospital,lahore, pakistan. patients who met eligibility criteria will be informed about the aim of study.all the eligible participants who will agree to participate will sign a consent form. after baseline assessment selected participants will be divided into 2 groups by random allocation method.subjects will be randomized into two groups using computer generated random numbers.the outcome assessor will be unaware of treatment given to both groups.the calculated sample size using numeric pain rating scale as outcome measure is 28 in each group, but after adding 20% dropout, the sample size will be 28+6=34 in each group, allowing statistical power of 80%and alpha level of 5%.

Eligibility criteria:
inclusion criteria: * both gender * participants with an age between 18 to 40 * participants diagnosed with chronic upper cross syndrome by orthopedic department for physical therapy treatment exclusion criteria: * trauma, tumor and fracture of upper limb and shoulder * congenital deformities of upper limb * history of any systemic disease * history of any neurological disease (epilepsy \&seizure, parkinson's disease) * history of recent surgery of spine or shoulder

Keywords: upper cross syndrome kinesio taping neck disability index goniometer pain
central blood pressure and pulse wave velocity in kidney transplant recipients

Conditions: End Stage Renal Disease

Summary: an observational cohort study will be conducted to non-invasively investigate central blood pressure and pulse wave velocity in children with kidney disease and controls. using an oscillometric monitor, the investigators aim to non-invasively obtain the central blood pressure and pulse wave velocity (pwv), or arterial stiffness, of children with kidney disease. the investigators will also enroll age- and race-matched healthy controls and measure the same parameters for comparison. in addition, the investigators will measure pwv by standard arterial tonometry method in a subset of patients.

the specific aims of the study are as follows: 1. using an oscillometric blood pressure monitor, the investigators aim to non-invasively obtain the central blood pressure and pulse wave velocity (pwv), or arterial stiffness, of children with kidney disease. 2. measure oscillometric central blood pressure and pwv in age and race matched healthy children. 3. measure pwv by standard arterial tonometry method in a subset of patients, and compare these measurements to the pwv measured using the oscillometric device. 4. measure body composition of patients and controls (body mass index, waist-to-height ratio, %body fat, and mid-arm muscle circumference) to see how this relates to central blood pressure and pwv.

Eligibility criteria:
inclusion criteria: * kidney transplant recipients who are at least 6 months post-transplant * healthy children matched for age sex and race exclusion criteria: * age less than 3 years
effects of short-term intensive insulin therapy in newly diagnosed type 2 diabetes patients

Conditions: Type 2 Diabetes Mellitus

Summary: it is well known that long-term hyperglycemia (also known as glucose toxicity) contribute to impairment in islet β-cell function and development of insulin resistance. a growing body of evidence also indicates that this impairment inβ-cell function and insulin action could be restored after hyperglycemia is corrected by short-term intensive insulin therapy. in this study, we are determined to use the golden standard of insulin sensitivity evaluation in vivo-hyperinsulinemia euglycemic glucose clamp-to estimate insulin resistance improvement in patients before and after intensive insulin therapy, investigate first phase insulin secretion to evaluate β-cell function, examine the changes in insulin resistance and insulin secretion resulting from normalization of plasma glucose levels in both lean and obese patients by insulin pump therapy.


Eligibility criteria:
inclusion criteria: * age: 25 to 60 years old * duration of diabetes: newly diagnosed type 2 diabetes (duration of diabetes less than 1 year) and haven't taken any antidiabetic medication. * fasting blood glucose is above 11.0mmol/l. * half of the patients with bmi below 24 and the other half with bmi above 24. exclusion criteria: * type 1 diabetes mellitus * type 2 diabetes patients with intercurrent illness (ketoacidosis, infection or any other acute stress) * presence of auto-immune disease, hepatic or renal disease or any concomitant disease is not allowed. * women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months.
short-term effect of intensive insulin therapy on incretin secretion

Conditions: Type 2 Diabetes

Summary: in type 2 diabetic patients, abnormality in secretion or action of incretin(glp-1, gip) is observed. although controversy still exists, the secretion of glp-1 is thought to be reduced by 20-30% while gip secretion is normal or slightly elevated, in type 2 diabetic patients. various parameters such as the duration of diabetes, the amount of meal and their constitution, gastric bypass surgery, and some antidiabetic drugs affect the secretion of incretin. however, the secretion of glp-1 and gip in glucotoxic condition and whether they recover after improvement of glycemic status is not known. the investigators aim to study the effect of intensive insulin treatment in uncontrolled diabetic patients.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients with disease duration of less than 15years * age of 20-70 years * bmi 22-27 * hba1c 9-13% * patients willing to receive intensive glucose control * patients who are able to monitor their glucose level at home * for normal glucose tolerance group : ngt subjects with same range of age and bmi * for early diabetes group : patients with diabetic duration of less than 5 years and hba1c level less than 7.5% for at least last 6 months exclusion criteria: * previous history of insulin treatment * patients taking alpha-glucosidase inhibitor or thiazolidinedione * serum creatinine \>= 1.5 mg/dl * hemoglobin \< 10 g/dl * ast/alt greater than 3 times normal range * ischemic heart disease, congestive heart failure (nyha grade \>=2) * chronic renal failure, proliferative diabetic retinopathy, cva * patients with gastroparesis or taking medications altering gastric motility * usage of steroid or other agents affecting glucose metabolism * pregnant or breast-feeding women

Keywords: incretin glp-1 gip intensive insulin therapy
small doses of dexmedetomidine for emergence agitation

Conditions: Emergence Agitation

Summary: dexmedetomidine hydrochloride is a kind of high selectivity alpha 2 agonists adrenaline, can inhibit the activity of sympathetic nerve, and reduce the adverse effects of stress reaction in anesthesia recovery period.literatures have been reported that dex can reduce the rate of emergence agitation of children and adults,especially in elderly patients(\>64 years) after using sevoflurane anesthesia.


Eligibility criteria:
inclusion criteria: 1. obtain informed consent; 2. patients whose selective under general anesthesia colorectal cancer or esophageal cancer radical operation time \> 2h; 3. the american society of anesthesiologists (asa) class i-ii; 4. age\>64 years old; 5. bmi\<28kg/㎡; exclusion criteria: 1. systolic pressure≥180mm hg or\<90mm hg, diastolic pressure≥110mm hg or\< 60mm hg; 2. serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections; 3. patients with difficult airway (such as mallampati airway class iii, airway abnormalities, etc.) 4. hr\<50times/min 5. a history of mental illness or a long history of taking medicine of psychiatric drugs and chronic analgesics 6. a history of alcoholism 7. diseases of the neuromuscular 8. a tendency to malignant hyperthermia 9. allergy to test drugs or have other contraindications 10. participated in other clinical drug researches over the past 30 days

Keywords: dexmedetomidine, agitation, afps, nrs, mean arterial pressure heart rate(hr)
effect of anesthetic method on optic nerve sheath diameter in patients undergoing ralp

Conditions: Prostate Cancer

Summary: the purpose of this study was to evaluate the effect of anesthetic method on the optic nerve sheath diameter in patients undergoing robot-assisted laparoscopic prostatectomy.

the purpose of this study was to evaluate the difference between the optic nerve sheath diameter measured during anesthesia with sevoflurane-remifentanil-dexmedetomidine and the optic nerve sheath diameter measured during anesthesia with sevoflurane-remifentanil in patients undergoing robot-assisted laparoscopic prostatectomy.

Eligibility criteria:
inclusion criteria: * undergone a robot-assisted laparoscopic prostatectomy with a prostate - cancer * 20 years of age or older and under 80 years of age * agree to participate in this study exclusion criteria: * history of cerebral hemorrhage or cerebral infarction * \< 20 years of age * ≥ 80 years of age * glaucoma * unexpected hemodynamic instability during surgery * failure to measure optic nerve sheath diameter * convert to open surgery
effect of intravenous lidocaine on serum mirna-135a in patients undergoing non-cardiac surgery

Conditions: Organ Protection

Summary: the purpose of this study is to investigate the effects of intravenous lidocaine on serum mirna-135a and its downstream proteins rock2 and add1 in elderly patients undergoing non-cardiac under general anesthesia.

postoperative cognitive dysfunction (pocd) is a major complication following surgeries and anesthesia, especially in elderly individuals. lidocaine, an inexpensive, widely available, and relatively safe compound, is a local anesthetic that readily crosses the blood-brain barrier. intravenous lidocaine can reduce the incidence of pocd. however, the mechanism is still unclear. rock2 and add1, which are regulated by mirna-135a, play a key role in learning, memory, and cognition. the objective of this study is to investigate the efficacy of intravenous lidocaine on the incidence of early pocd, and the levels of rock2, add1, and mirna-135a in elderly patients undergoing non-cardiac under general anesthesia.

Eligibility criteria:
inclusion criteria: * patients undergoing elective non-cardiac surgery under general anesthesia * asa physical status ii-iii * aged ≥65 years exclusion criteria: * serious heart, lung, liver and kidney diseases * central nervous system injury * mental illness and drug dependence * on regular use of analgesic/sedative/antidepressant * unable to cooperate * allergy to lidocaine * mmse \< 23 points

Keywords: lidocaine postoperative cognitive dysfunction mirna-135a rock2 add1
proactive therapeutic drug monitoring based adalimumab therapy optimization in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: current standard of care of rheumatoid arthritis (ra) management includes a routine clinical assessment of disease activity to adjust therapy. for the most part, therapy adjustment for therapy non-response and/or suboptimal therapy response leads to therapy switch within the same class of therapy or to a different class of therapy. the lack of objective data to titrate dose of a given therapeutic agent for maximal possible efficacy makes it difficult for providers and payors to titrate dose as needed. therapeutic drug monitoring (tdm) provides objective data for a proactive and individualized therapy optimization based on serum drug levels and the presence or absence of anti-drug antibodies. maintaining optimal trough drug concentration is a proven concept of therapeutics. with respect to adalimumab, this approach helps to maximize therapeutic efficacy and prevent anti-adalimumab antibody development. however, lack of drug and disease state specific published data creates a barrier for a wider adoption of tdm into clinical practice. the objective of this single site, open label, randomized, parallel group pilot study is to investigate whether proactive therapeutic drug monitoring based adalimumab dose optimization results in higher rate of achieving and/or maintaining therapeutic goal compared to standard of care in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis * starting or already being treated with standard dose adalimumab, 40 mg subcutaneously (sq) every two weeks * good medication adherence rate defined as proportion of days covered (pdc) 80% and above exclusion criteria: * detectable anti-adalimumab antibodies * overlapping immune mediated diseases * steroid therapy for more than 2 months prior to study enrollment * poor medication adherence rate (pdc \< 80%) * history of recurrent infection resulting in therapy pause * pregnant or lactating

Keywords: therapeutic drug monitoring (tdm) optimal trough drug concentration adalimumab dose optimization routine assessment of patient index data 3 (rapid3)
evaluation of toothpaste on dental plaque

Conditions: Dental Plaque

Summary: the aim of this study is to compare the plaque reduction efficacy of toothpaste to a marketed active magnesium toothpaste with single-use brushing in children.our study will consist of 50 people between the ages of 9-12. 50 people will take part in both toothpaste groups.

the upper anterior incisor teeth of 50 children will be brushed with two different toothpaste in with a 2 week washout period.at the same time, the gc d lite pro curing light will determine to differences in the amount of plaque by using detection mode and the differences amount of plaque on teeth will be recorded with using plaque dye.

Eligibility criteria:
inclusion criteria: * patients aged 9-12 years * the presence of caries-free and fully erupted upper anterior incisors that can be scored in the mouth * absence of orthodontic appliances/brackets * no physical limitations * no previous trauma history * it was determined as the absence of soft-hard tissue pathology. exclusion criteria: * patients not between 9-12 years * the presence of decay and not fully erupted upper anterior incisors that can be scored in the mouth * presence of orthodontic appliances/brackets * physical limitations * previous trauma history * it was determined as the presence of soft-hard tissue pathology.
oral curcumin, quercetin and vitamin d3 supplements for mild to moderate symptoms of covid-19

Conditions: Covid-19

Summary: the present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin d3 as add-on therapy to the routine care for early mild symptoms of covid-19 infection in outpatients setting.

there is currently no specific early-stage therapeutic treatment available for covid-19. dietary supplements curcumin, quercetin and vitamin d3 have shown strong antioxidant, anti-inflammatory/immunomodulatory and broad-spectrum antiviral effects. the present study is focused to test the combination of oral curcumin, quercetin and vitamin d3 supplements as complementary therapy for outpatients with mild to moderate symptoms of covid-19 infection.

Eligibility criteria:
inclusion criteria: * patients must be 18 years of age or older, of either gender * patients must be tested positive for sars-cov-2 by rt-pcr within 72 hours prior to enrolment * patients must exhibit typical symptoms of covid-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc. * patients must be in the early stage of covid-19 disease who do not require hospitalization at the time of screening * patients must be under the care of a physician for diagnosis of covid-19 * patients who have signed informed consent exclusion criteria: * patients with proven hypersensitivity or allergic reaction to quercetin or curcumin * patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis * patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * patients taking anticoagulant/antiplatelet drugs such as coumarine, heparine, aspirin, clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. * patients with gallstone obstruction * hypothyroid suffering patients * patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/l); * pregnant patients
nitrates and il-8 in barrett's esophagus

Conditions: Barrett Esophagus; Esophageal Adenocarcinoma

Summary: the purpose of this study is to determine if nitrates and il-8 (which are found in food and throughout the body regulating stomach acidity) play a role in barrett's esophagus and/or esophageal adenocarcinoma severity and if screening for these biomarkers can help predict patients that are more at risk for developing worsening disease.


Eligibility criteria:
inclusion criteria: - patients undergoing a clinicallly-indicated esophagogastroduoedoscopy (egd). exclusion criteria: * comorbid inflammatory medical condition. * use of antiinflammatory (aspirin and nsaids) or immunosuppressants over the past 1 week. * use of nitrate containing medication in the past 1 week. * consumption of nitrate rich foods in preceding 24 hours. * known allergy to meat or nitrates
comparing the effects of m-tapa and tap block on postoperative analgesia in tah

Conditions: Postoperative Pain

Summary: aim is to compare the postoperative analgesic efficacy of m-tapa block and tap block and their effect on opioid consumption in patients undergoing open total abdominal hysterectomy (tah) surgery.

there were three randomized groups: group m (m-tapa block) (n=15), group t (tap block) (n=15) and group c (no block) (n=15). all patients had standard general anesthesia. group m had bilateral m-tapa block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery. group t patients had tap block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery. group control had only tramadol for postoperative pain. numerical rating scale (nrs) was used to assess postoperative pain on 1st, 6th, 12th and 24th hour after the surgery. total tramadol consumption was calculated.

Eligibility criteria:
inclusion criteria: * adult patients older than 35 years of age who underwent open total abdominal hysterectomy under general anesthesia and were american society of anesthesiologists (asa) i-ii-iii according to the asa risk classification. exclusion criteria: * patients who did not give consent, * patients with coagulopathy, * patients with signs of infection at the block application site, * patients using anticoagulants, * patients with local anesthetic drug allergies, * patients undergoing laparoscopic surgery, * patients with unstable hemodynamics, * patients who could not cooperate during postoperative pain assessment

Keywords: m-tapa tap block total abdominal hysterectomy regional anesthesia postoperative pain